AstraZeneca and MSD’s Lynparza is a step closer to being cleared in Europe as maintenance therapy for some patients with ovarian cancer.
Gilead’s Kite is linking with Sangamo Therapeutics in a collaboration that aims to develop next-generation engineered cell therapies for the treatment of cancer.
Big data is showering its miraculous effects on a range of industries. And the healthcare industry is not left out of the bandwagon. Precision medicine is at the brink of a revolution in individualizing treatment, and healthcare professionals are devising ways to prevent and treat diseases with granularity down to a single patient’s genome.
Cost regulators for NHS treatments in England and Wales are sticking with their position that Eisai’s Halaven should not be funded by the NHS as a second-line of attack against a certain form of breast cancer.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2017.
It’s flu season, and many of us find ourselves glancing nervously at anyone coughing or sniffling in our vicinity. But how, besides shielding ourselves from public sneezers, do we avoid coming into contact with infections?
Human eggs have been fully grown in a laboratory for the first time in what has been hailed as a majorfertility breakthrough.
A San Francisco, California-based medical device startup, Zenflow, has announced a $31.4 million Series A financing round to further its minimally-invasive approach to treating benign prostatic hyperplasia (BPH) or enlarged prostate.
Following a soft launch last year, the chemoWave disease companion app has now been fully released for chemotherapy patients interested in better managing their care, symptoms, and side effects.
Surgeons in the UK are using Microsoft’s mixed-reality headset to “see inside” patients before they operate on them.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.